Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 7:21 pm Sale | 2024-09-30 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Lind Global Fund II LP | 0 0.000% | -426 (Position Closed) | Filing History |
| 2024-11-14 3:27 pm Purchase | 2024-09-30 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Armistice Capital, LLC | 928 9.990% | 928 (New Position) | Filing History |
| 2024-02-14 4:31 pm Sale | 2023-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Schonfeld Strategic Advisors LLC | 8 0.180% | -206 (-96.30%) | Filing History |
| 2024-02-14 10:09 am Sale | 2023-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Dellora Investments Master Fund LP | 0 0.000% | -180 (Position Closed) | Filing History |
| 2024-02-13 3:47 pm Unchanged | 2023-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Altium Capital Management LLC | 809 4.990% | 0 (Unchanged) | Filing History |
| 2024-02-07 5:03 pm Sale | 2023-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | ACORN BIOVENTURES, L.P. | 0 0.000% | -782 (Position Closed) | Filing History |
| 2024-01-10 1:35 pm Purchase | 2023-12-21 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Altium Capital Management LLC | 809 8.000% | 809 (New Position) | Filing History |
| 2024-01-04 4:30 pm Purchase | 2023-12-26 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Lind Global Fund II LP | 426 9.900% | 426 (New Position) | Filing History |
| 2023-02-14 4:31 pm Purchase | 2022-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Schonfeld Strategic Advisors LLC | 214 6.140% | 214 (New Position) | Filing History |
| 2023-02-13 4:16 pm Unchanged | 2022-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Dellora Investments Master Fund LP | 180 5.200% | 0 (Unchanged) | Filing History |
| 2023-02-06 11:27 am Sale | 2022-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | SPHERA FUNDS MANAGEMENT LTD. | 69 1.990% | -72 (-50.82%) | Filing History |
| 2023-01-26 1:36 pm Purchase | 2022-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | ACORN BIOVENTURES, L.P. | 782 9.990% | 131 (+20.07%) | Filing History |
| 2022-08-22 1:17 pm Purchase | 2022-08-11 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Dellora Investments Master Fund LP | 180 5.200% | 180 (New Position) | Filing History |
| 2022-02-14 4:34 pm Sale | 2021-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Ikarian Capital, LLC | 28 1.000% | -83 (-75.14%) | Filing History |
| 2022-02-14 06:15 am Purchase | 2021-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | SPHERA FUNDS MANAGEMENT LTD. | 141 5.100% | 0 (+0.30%) | Filing History |
| 2022-02-04 4:03 pm Unchanged | 2021-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Hudson Bay Capital Management LP | 115 3.970% | 0 (Unchanged) | Filing History |
| 2021-03-18 12:59 pm Purchase | 2021-03-12 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | SPHERA FUNDS MANAGEMENT LTD. | 141 6.290% | 141 (New Position) | Filing History |
| 2021-02-16 09:57 am Purchase | 2020-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | CVI Investments, Inc. | 78 4.900% | 0 (+0.46%) | Filing History |
| 2021-02-12 4:58 pm Purchase | 2020-12-18 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | ACORN BIOVENTURES, L.P. | 651 9.990% | 651 (New Position) | Filing History |
| 2021-02-11 09:41 am Unchanged | 2020-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Renaissance Technologies LLC | 0 0.000% | 0 (Unchanged) | Filing History |